Table III.
Comparison of survival months and non-treatment rate following diagnostic surgery across age groups.
| Variables | Aged 66–74 years (n=1,951) | Aged ≥75 years (n=1,808) | P-valuea |
|---|---|---|---|
| Survival months, median (range) | |||
| All patients | 8 (0–121) | 4 (0–95) | <0.0001 |
| Surgery, no RT, no TMZ | 2 (0–61) | 2 (0–89) | <0.0001b |
| Surgery, HRT, no TMZ | 5 (0–31) | 4 (0–33) | 0.0671 |
| Surgery, SRT, no TMZ | 10 (1–121) | 7 (1–95) | <0.0001 |
| Surgery, HRT, TMZ | 5 (1–21) | 3 (1–29) | 0.8314 |
| Surgery, SRT, TMZ | 11 (2–56) | 9 (2–31) | <0.0001 |
| Surgery, no RT, TMZ | 5 (1–24) | 6 (1–24) | 0.7289 |
| Non-treatment rate following diagnostic surgery | |||
| Number of non-treated patients (%) | 401 (20.55) | 693 (38.33) | <.0001 |
a
For the survival analysis, this is the log-rank test comparing the overall survival times. For the non-treatment rate, this is the Chi-square P-value comparing the rates.
b
Although the two age groups have the same median survival, patients aged 66–74 years exhibited a higher overall survival. TMZ, temozolomide; RT, radiation therapy; HRT, hypofractionated RT; SRT, standard RT.